CHMP also recommends XELJANZ® (tofacitinib) approval for the treatment of adults with active ankylosing spondylitis NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the
DUBLIN–(BUSINESS WIRE)–The “Global Autoimmune Disorder Drug Delivery Devices Market Research Report: Forecast (2021-2026)” report has been added to ResearchAndMarkets.com’s offering. According to the report, the
UK-based biotech company Silence Therapeutics has announced a collaboration with Hansoh Pharma to develop novel short interfering ribonucleic acid (siRNA) therapeutics for three undisclosed targets.
WOODSTOCK, Ga.–(BUSINESS WIRE)–Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications,
AstraZeneca’s drug combination Imfinzi plus tremelimumab has been shown to significantly improve overall survival for patients with first-line unresectable liver cancer. The positive high-level results